Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Five patients were randomly assigned to each treatment schedule in a 3-month prospective, double-blind clinical trial.

Three of the 10 patients, none taking zidovudine and all with low initial CD4 counts, were withdrawn during the study due to acute opportunistic infections.

Who Took Part

The study group was 10 patients.

The age groups tagged for this paper are adults and middle-aged adults, men only.

How the Study Was Run

The design is described as randomized and double-blind.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

What Was Measured

Topics PubMed links to this paper include AIDS-Related Complex, Acquired Immunodeficiency Syndrome, Body Composition, Body Water, Growth Hormone, Insulin-Like Growth Factor I and Leukocyte Count.

What This Means in Plain Language

The paper is a randomized and double-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 10 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1993 (Journal of acquired immune deficiency syndromes), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.